{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:09:50Z","timestamp":1778821790243,"version":"3.51.4"},"reference-count":7,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jtho.2025.12.005","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T09:36:37Z","timestamp":1770197797000},"page":"338-339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Response to the Letter to the Editor: \u201cComment on COCOON: Daily 4% Chlorhexidine for Nail Care\u2014Rationale, Safety, and Evidence Gaps\u201d"],"prefix":"10.1016","volume":"21","author":[{"given":"Byoung Chul","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxwell","family":"Sauder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jairo","family":"Simoes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2025.12.005_bib1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jtho.2025.10.011","article-title":"Comment on COCOON: daily 4% chlorhexidine for nail care\u2013rationale, safety, and evidence gaps","volume":"21","author":"Kunimasa","year":"2026","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.12.005_bib2","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.jtho.2025.07.117","article-title":"Enhanced versus standard dermatologic management with amivantamab-lazertinib in EGFR-mutated advanced NSCLC: the COCOON global randomized controlled trial","volume":"20","author":"Cho","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.12.005_bib3","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","article-title":"Overall survival with amivantamab-lazertinib in EGFR-mutated advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.12.005_bib4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.cmi.2018.09.012","article-title":"Daily bathing with 4% chlorhexidine gluconate in intensive care settings: a randomized controlled trial","volume":"25","author":"Pallotto","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jtho.2025.12.005_bib5","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s40265-015-0434-6","article-title":"Expert Consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK","volume":"75","author":"Califano","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.jtho.2025.12.005_bib6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.abd.2020.01.001","article-title":"Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel","volume":"95","author":"Cury-Martins","year":"2020","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.jtho.2025.12.005_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102584","article-title":"5MO Effect of amivantamab dose interruptions on efficacy and safety of first-line amivantamab plus lazertinib in EGFR-mutant advanced NSCLC: exploratory analyses from the MARIPOSA study","volume":"9","author":"Garc\u00eda Campelo","year":"2024","journal-title":"ESMO Open"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425029430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425029430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:28:22Z","timestamp":1778819302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086425029430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":7,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1556086425029430"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2025.12.005","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Response to the Letter to the Editor: \u201cComment on COCOON: Daily 4% Chlorhexidine for Nail Care\u2014Rationale, Safety, and Evidence Gaps\u201d","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2025.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2025.10.011","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}